AGRX News and Press, Agile Therapeutics Inc. From 02/27/20

Shares of the early commercial stage biotech Agile Therapeutics (NASDAQ: AGRX) are in a tailspin Thursday morning. The drugmaker's stock is down by 20.5% as of 10:12 a.m. EST today. Following this latest downward move, Agile's stock has now lost over a third of its value since the start of ...

PRINCETON, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times Square on Wednesday, February 26, 2020. In honor of the occasion, A...

After sharing the pricing information of a just-announced common stock offering, Agile Therapeutics   (NASDAQ: AGRX) , a clinical-stage biopharma focused on women's health, saw its stock fall 14% as of 3:22 p.m. EST on Friday. Agile announced on Thursday that it wanted to raise capit...

TrueCar (NASDAQ: TRUE )  -29%  after guidance disappoints. More news on: TrueCar, Inc., BlueLinx Holdings Inc., EyePoint Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Agile Therapeutics (NASDAQ: AGRX ) has priced its public offering of 15M common shares at $3.00 per share. Underwriters' over-allotment is an additional 2.25M shares. Closing date is February 25. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Re...

PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross ...

Agile Therapeutics (NASDAQ: AGRX ): Q4 GAAP EPS of -$0.10 misses by $0.02 . Cash and equivalents of $34.5M. Shares -14.3% . Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla ® , Company’s Lead Product Candidate, Receives FDA Approval Company Plans to Commence Distributing Product to Wholesalers in the Fourth Quarter of 2020 PRI...

You've heard the old saying, "If at first you don't succeed, try, try again." Agile Therapeutics (NASDAQ: AGRX) just proved the wisdom of the adage. In December 2017, Agile received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its contraceptive pat...

Summer Infant (NASDAQ: SUMR ) -25% . More news on: Summer Infant, Inc., Westwater Resources, Inc., Fluor Corporation, Stocks on the move, , Read more ...